Research programme: sigma receptor modulators - Anavex Life Sciences

Drug Profile

Research programme: sigma receptor modulators - Anavex Life Sciences

Alternative Names: ANAVEX 1005; ANAVEX 1007; ANAVEX 1066; ANAVEX 1067; ANAVEX 1079; ANAVEX 1519; ANAVEX 27-1041; ANAVEX 28-1078; ANAVEX 30-1022; ANAVEX 35-3016; ANAVEX 40-1042; ANAVEX 7-1037; ANAVEX 8-142; Cancer therapeutics - Anavex Life Sciences; Sigmaceptor-C™ programme

Latest Information Update: 18 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anavex Life Sciences
  • Class Small molecules
  • Mechanism of Action Chloride channel modulators; Muscarinic M3 receptor antagonists; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sigma-2 receptor agonists; Sigma-2 receptor antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute pain; Malignant melanoma; Neuropathic pain; Ovarian cancer; Pain; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 14 Nov 2016 Pharmacodynamics data from preclinical studies in Pain released by Anavex Life Sciences
  • 03 Nov 2015 Preclinical trials in Ovarian cancer in Switzerland (unspecified route) (Anavex pipeline, November 2015)
  • 01 May 2012 Preclinical trials in Acute pain in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top